117 related articles for article (PubMed ID: 6420144)
21. Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine.
Atiba JO; Blaschke TF; Wilkinson GR
Br J Clin Pharmacol; 1989 Aug; 28(2):161-5. PubMed ID: 2775621
[TBL] [Abstract][Full Text] [Related]
22. Relation of in vivo drug metabolism to stereoselective fetal hydantoin toxicology in mouse: evaluation of mephenytoin and its metabolite, nirvanol.
Wells PG; Küpfer A; Lawson JA; Harbison RD
J Pharmacol Exp Ther; 1982 Apr; 221(1):228-34. PubMed ID: 7062285
[TBL] [Abstract][Full Text] [Related]
23. Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2.
Yasumori T; Murayama N; Yamazoe Y; Kato R
Clin Pharmacol Ther; 1990 Mar; 47(3):313-22. PubMed ID: 2311333
[TBL] [Abstract][Full Text] [Related]
24. Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians.
Jurima M; Inaba T; Kadar D; Kalow W
Br J Clin Pharmacol; 1985 Apr; 19(4):483-7. PubMed ID: 3994895
[TBL] [Abstract][Full Text] [Related]
25. Family studies of mephenytoin hydroxylation deficiency.
Inaba T; Jurima M; Kalow W
Am J Hum Genet; 1986 May; 38(5):768-72. PubMed ID: 3717162
[TBL] [Abstract][Full Text] [Related]
26. Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man.
Wedlund PJ; Sweetman BJ; Wilkinson GR; Branch RA
Drug Metab Dispos; 1987; 15(2):277-9. PubMed ID: 2882992
[No Abstract] [Full Text] [Related]
27. S-mephenytoin 4-hydroxylase is inherited as an autosomal-recessive trait in Japanese families.
Ward SA; Goto F; Nakamura K; Jacqz E; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1987 Jul; 42(1):96-9. PubMed ID: 3595072
[TBL] [Abstract][Full Text] [Related]
28. Stereochemical aspects of the metabolism of 5-ethyl-5-phenylhydantoin (Nirvanol) in the dog.
Maguire JH; Kraus BL; Butler TC; Dudley KH
Drug Metab Dispos; 1981; 9(5):393-401. PubMed ID: 6117436
[TBL] [Abstract][Full Text] [Related]
29. Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin.
Zhou HH; Anthony LB; Wood AJ; Wilkinson GR
Br J Clin Pharmacol; 1990 Sep; 30(3):471-5. PubMed ID: 2223426
[TBL] [Abstract][Full Text] [Related]
30. Evidence for an arene oxide-NIH shift pathway in the metabolic conversion of phenytoin to 5-(4-hydroxyphenyl)-5-phenylhydantoin in the rat and in man.
Claesen M; Moustafa MA; Adline J; Vandervorst D; Poupaert JH
Drug Metab Dispos; 1982; 10(6):667-71. PubMed ID: 6130920
[TBL] [Abstract][Full Text] [Related]
31. Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping tests.
Spina E; Buemi AL; Sanz E; Bertilsson L
Ther Drug Monit; 1989 Nov; 11(6):721-3. PubMed ID: 2595755
[TBL] [Abstract][Full Text] [Related]
32. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians.
Inaba T; Jurima M; Nakano M; Kalow W
Clin Pharmacol Ther; 1984 Nov; 36(5):670-6. PubMed ID: 6488688
[TBL] [Abstract][Full Text] [Related]
33. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.
Bertilsson L; Henthorn TK; Sanz E; Tybring G; Säwe J; Villén T
Clin Pharmacol Ther; 1989 Apr; 45(4):348-55. PubMed ID: 2495208
[TBL] [Abstract][Full Text] [Related]
34. Stereoselective metabolism and disposition of the enantiomers of mephenytoin during chronic oral administration of the racemic drug in man.
Küpfer A; Desmond PV; Schenker S; Branch RA
J Pharmacol Exp Ther; 1982 Jun; 221(3):590-7. PubMed ID: 7086673
[No Abstract] [Full Text] [Related]
35. Mephenytoin stereoselective elimination in the rat: II. Comparison of mephenytoin stereoselective clearance during chronic intravenous and hepatic portal vein administration.
Akrawi SH; Wedlund PJ
Eur J Drug Metab Pharmacokinet; 1989; 14(4):269-78. PubMed ID: 2633921
[TBL] [Abstract][Full Text] [Related]
36. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily.
Relling MV; Aoyama T; Gonzalez FJ; Meyer UA
J Pharmacol Exp Ther; 1990 Jan; 252(1):442-7. PubMed ID: 2299601
[TBL] [Abstract][Full Text] [Related]
37. Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A).
Yasumori T; Chen L; Nagata K; Yamazoe Y; Kato R
J Pharmacol Exp Ther; 1993 Jan; 264(1):89-94. PubMed ID: 8423554
[TBL] [Abstract][Full Text] [Related]
38. Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.
Ieiri I; Mamiya K; Urae A; Wada Y; Kimura M; Irie S; Amamoto T; Kubota T; Yoshioka S; Nakamura K; Nakano S; Tashiro N; Higuchi S
Br J Clin Pharmacol; 1997 Apr; 43(4):441-5. PubMed ID: 9146858
[TBL] [Abstract][Full Text] [Related]
39. Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate.
Horsmans Y; Lannes D; Pessayre D; Larrey D
J Hepatol; 1994 Dec; 21(6):1075-9. PubMed ID: 7699230
[TBL] [Abstract][Full Text] [Related]
40. Genetic polymorphism of S-mephenytoin 4'-hydroxylation.
Daniel HI; Edeki TI
Psychopharmacol Bull; 1996; 32(2):219-30. PubMed ID: 8783891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
